Piramal Pharma Solutions (PPS) has invested $55 million across its sites in North America & Asia, to expand its active pharmaceutical ingredient (API) manufacturing capabilities and capacities.
PPS is a leading contract development and manufacturing organisation (CDMO) and part of Piramal Enterprises Ltd (PEL).
A part of this investment will go into new state-of-the-art, multi-purpose plants, with over 270 kiloliters of total capacity, to support the current pipeline of approximately 80 late-stage programs that PPS is currently assisting its partners with at various global sites.
PPS will also expand its potency footprint at its plant in Riverview, Michigan, while augmenting early development capabilities out of Ennore, India through additions of GMP kilo labs and a pilot plant.
To serve its European biotech customers better, PPS will add early development capabilities in both, drug substance and drug product, out of its Morpeth, UK facility.
Support functions such as analytical capabilities, R&D infrastructure, automation, and IT systems will also be expanded at all API sites through this investment.
No comments:
Post a Comment